Premier Biotech Respiratory Test Kit RightSign™ Antibody Test COVID-19 IgG / IgM Whole Blood / Serum / Plasma Sample 20 Tests CLIA Waived for Fingerstick Whole Blood - Case of 20 - RT-CV19-20-CS
Premier Biotech Respiratory Test Kit RightSign™ Antibody Test COVID-19 IgG / IgM Whole Blood / Serum / Plasma Sample 20 Tests CLIA Waived for Fingerstick Whole Blood - Case of 20 - RT-CV19-20-CS
Regular price
$206.99
Sale price
$206.99
Regular price
Unit price
per
Shipping calculated at checkout.
50 In stock
Estimated deliver:
Flat-Rate Shipping from $8.25
Premier Biotech Respiratory Test Kit RightSign™ Antibody Test COVID-19 IgG / IgM Whole Blood / Se...
| Item Id | 1163497 |
| MF Id# | RT-CV19-20 |
| Brand | RightSign™ |
| Manufacturer | Premier Biotech |
| Country of Origin | China |
| Application | Respiratory Test Kit |
| CLIA Classification | CLIA Waived for Fingerstick Whole Blood |
| CLIA Classified | CLIA Waived Sample Dependent |
| Contents 1 | (20) Cassettes, 1 X 3 mL Buffer, (20) Capillaries, Package Insert, Procedure Card, (20) Lancets, (20) Pads |
| For Use With | For the Qualitative Detection of SARS-CoV-2 Antibodies in Whole Blood, Serum or Plasma |
| Number of Tests | 20 Tests |
| Product Dating | McKesson Acceptable Dating: we will ship >= 30 days |
| Purchase Program Type | Standard Purchase |
| Reading Type | Visual Read |
| Sample Type | Whole Blood / Serum / Plasma Sample |
| Specialty | Immunoassay |
| Technology | Lateral Flow Technology |
| Test Format | Cassette Format |
| Test Method | Chromatographic Immunoassay |
| Test Name | COVID-19 IgG / IgM |
| Test Type | Antibody Test |
| Time to Results | 10 Minute Results |
| UNSPSC Code | 41116205 |
| Volume | 3 mL Buffer |
Features
- Testing of serum, plasma and venous whole blood specimens is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests
- Testing of fingerstick whole blood specimens is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate or waived complexity tests
- Product ships from McKesson with minimum 30 days dating
- Testing of fingerstick whole blood specimens is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
- RightSign™ COVID-19 IgG/IgM Rapid Test Cassette should not be used to diagnose acute SARS-CoV-2 infection
- Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities
- False positive results may occur due to cross-reactivity from pre-existing antibodies or other possible causes
- Due to the risk of false positive results, confirmation of positive results should be considered using second, different IgG or IgM assay
- RightSign™ COVID-19 IgG/IgM Rapid Test Cassette is a rapid lateral flow chromatographic immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in in human venous whole blood (sodium heparin, EDTA, and sodium citrate), serum or plasma (sodium heparin, potassium EDTA and sodium citrate)
- This test uses anti-human IgM antibody (test line IgM), anti-human IgG (test line IgG) and goat anti-mouse IgG (control line C) immobilized on a nitrocellulose strip
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the authorization is terminated or revoked sooner
- RightSign™ COVID-19 IgG/IgM Rapid Test Cassette is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection